Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center
Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy's drug and poison information center (DPIC). Methods: In this study, data of patients receiving...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center for Rational Use of Drugs (RCRUD)
2023-09-01
|
| Series: | Journal of Pharmaceutical Care |
| Subjects: | |
| Online Access: | https://jpc.tums.ac.ir/index.php/jpc/article/view/590 |
| _version_ | 1797658918559678464 |
|---|---|
| author | Amirhosein Ghahremanian Hasti Photography Sona Ghasemi Mohammadreza Heidari Elliyeh ghadrdan |
| author_facet | Amirhosein Ghahremanian Hasti Photography Sona Ghasemi Mohammadreza Heidari Elliyeh ghadrdan |
| author_sort | Amirhosein Ghahremanian |
| collection | DOAJ |
| description |
Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy's drug and poison information center (DPIC). Methods: In this study, data of patients receiving remdesivir who contacted the 13-Aban pharmacy's DPIC between April 2021 and May 2022 were extracted. For the evaluation of potential ADEs, we reviewed all contacts related to remdesivir recipients. Results: Out of 223 patients enrolled, 108 (48.40%) developed 120 ADEs. Elevated liver transaminase levels (26.67%) were the most common ADE, followed by weakness (7.5%), nausea, and vomiting (7.5%). The causality assessment of ADE using the Naranjo scale revealed that 41.67% were probable and 58.33% were possible. Conclusion: Based on the results of this study, hepatic dysfunction was the most prevalent ADE among remdesivir recipients; thus, in order to ensure safe use of remdesivir, patients should be closely monitored for this ADE.
|
| first_indexed | 2024-03-11T18:06:20Z |
| format | Article |
| id | doaj.art-9700caf8851f47e1bef6d716734e7b6d |
| institution | Directory Open Access Journal |
| issn | 2322-4630 2322-4509 |
| language | English |
| last_indexed | 2024-03-11T18:06:20Z |
| publishDate | 2023-09-01 |
| publisher | Research Center for Rational Use of Drugs (RCRUD) |
| record_format | Article |
| series | Journal of Pharmaceutical Care |
| spelling | doaj.art-9700caf8851f47e1bef6d716734e7b6d2023-10-17T05:30:39ZengResearch Center for Rational Use of Drugs (RCRUD)Journal of Pharmaceutical Care2322-46302322-45092023-09-01113Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information CenterAmirhosein Ghahremanian0Hasti Photography1Sona Ghasemi2Mohammadreza Heidari3Elliyeh ghadrdan4Department of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Pharmacy, 13‑Aban Drug and Poison Information Center, Tehran University of Medical Sciences, Tehran, IranDepartment of Clinical Pharmacy. Faculty of Pharmacy, Alborz University of Medical Sciences, Karaj, Iran. 3Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran Background: One of the FDA-approved treatments for COVID-19 is remdesivir. In this study, we investigated adverse drug events (ADEs) of remdesivir in COVID-19 patients who contacted 13-Aban pharmacy's drug and poison information center (DPIC). Methods: In this study, data of patients receiving remdesivir who contacted the 13-Aban pharmacy's DPIC between April 2021 and May 2022 were extracted. For the evaluation of potential ADEs, we reviewed all contacts related to remdesivir recipients. Results: Out of 223 patients enrolled, 108 (48.40%) developed 120 ADEs. Elevated liver transaminase levels (26.67%) were the most common ADE, followed by weakness (7.5%), nausea, and vomiting (7.5%). The causality assessment of ADE using the Naranjo scale revealed that 41.67% were probable and 58.33% were possible. Conclusion: Based on the results of this study, hepatic dysfunction was the most prevalent ADE among remdesivir recipients; thus, in order to ensure safe use of remdesivir, patients should be closely monitored for this ADE. https://jpc.tums.ac.ir/index.php/jpc/article/view/590Remdesivir, COVID-19, DPIC, Adverse drug events |
| spellingShingle | Amirhosein Ghahremanian Hasti Photography Sona Ghasemi Mohammadreza Heidari Elliyeh ghadrdan Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center Journal of Pharmaceutical Care Remdesivir, COVID-19, DPIC, Adverse drug events |
| title | Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center |
| title_full | Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center |
| title_fullStr | Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center |
| title_full_unstemmed | Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center |
| title_short | Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center |
| title_sort | evaluation of adverse drug events of remdesivir for the treatment of covid 19 in patients contacting the 13 aban pharmacy drug and poison information center |
| topic | Remdesivir, COVID-19, DPIC, Adverse drug events |
| url | https://jpc.tums.ac.ir/index.php/jpc/article/view/590 |
| work_keys_str_mv | AT amirhoseinghahremanian evaluationofadversedrugeventsofremdesivirforthetreatmentofcovid19inpatientscontactingthe13abanpharmacydrugandpoisoninformationcenter AT hastiphotography evaluationofadversedrugeventsofremdesivirforthetreatmentofcovid19inpatientscontactingthe13abanpharmacydrugandpoisoninformationcenter AT sonaghasemi evaluationofadversedrugeventsofremdesivirforthetreatmentofcovid19inpatientscontactingthe13abanpharmacydrugandpoisoninformationcenter AT mohammadrezaheidari evaluationofadversedrugeventsofremdesivirforthetreatmentofcovid19inpatientscontactingthe13abanpharmacydrugandpoisoninformationcenter AT elliyehghadrdan evaluationofadversedrugeventsofremdesivirforthetreatmentofcovid19inpatientscontactingthe13abanpharmacydrugandpoisoninformationcenter |